Company Overview and Milestones - Sharps Technology was founded in 2017 and completed its IPO in 2022, raising $16 million[3] - The company acquired SafeGard Medical in Hungary in July 2022, a facility producing specialty safety syringes[3] - In May 2024, Sharps Technology signed an Asset and Syringe Sales Agreement with Nephron and InjectEZ[4] - A $20 million underwritten public offering was closed in January 2025[5] Manufacturing and Product Line - The company has an operational manufacturing facility in Hungary (~40k Sq Ft) and a pending facility in Columbia, South Carolina (~100k Sq Ft)[10, 12] - The Hungary facility has a capacity of 45 million units, expandable to 200 million units[23] - The South Carolina facility is expected to have a capacity of 60 million units per year, expandable to 90 million units per year[28, 29] - Sharps Technology has a product line of patented smart safety syringe systems, including Securegard, Provensa, Sologard Locking +, and Sologard[6, 14] Sales and Financials - A multi-year agreement with a U S leader in IV flushing solutions is expected to generate over $50 million in revenue over five years, with first shipments in Q2 2025[4] - The company received a $400,000 purchase order in June 2025 and began shipments for SoloGard[34] - The agreement for SoloGard could involve +500 million units over five years[36] - The company has $11.9 million in cash and no debt[67] Market Overview - The global syringe market was valued at $22.5 billion in 2023, with a CAGR of approximately 9.2%[39, 40] - The disposable syringe market was valued at $13.1 billion in 2023, with a CAGR of approximately 6.1%[43, 44] - The prefillable syringe market was valued at $8.1 billion in 2023[39]

Second commercial delivery underway as part of multi-year contract with leading U.S. healthcare partnerStrategic manufacturing upgrades drive scalability, efficiency, and increases capacity to support production growth NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced an update o ...

Summary of Sharps Technology (STSS) Conference Call Company Overview - **Company Name**: Sharps Technology - **Ticker Symbol**: STSS - **Industry**: Drug delivery and medical devices, specializing in smart safety syringes and prefillable syringes - **Founded**: 2017, IPO completed in 2022 [4][2] Key Points and Arguments Business Developments - **Sales Agreement**: Signed a $50 million agreement to supply SoloGuard products to a U.S. drug filler, with initial shipments starting this quarter [7][24] - **Funding**: Successfully raised $20 million to expand the European facility to support the sales agreement [8][51] - **Product Commercialization**: Successfully commercialized three products: SoloGuard, SecurGuard, and a syringe for auto injectors [8][9] Facilities - **European Facility**: - Located in Hungary, fully operational with no debt [10][11] - 40,000 to 45,000 square feet, expandable for future sales agreements [11] - **South Carolina Facility**: - Under negotiation for acquisition, 100,000 square feet, specialized for prefilled syringes [12][21] Product Lines - **Smart Safety Syringes**: Focus on low waste and reuse prevention technologies [16][29] - **Prefilled Syringes**: High-value products with significant revenue potential, transitioning from glass to copolymer materials for better manufacturing efficiency [17][23][29] Market Dynamics - **Growth Potential**: The syringe market, particularly disposable and prefilled syringes, is one of the fastest-growing segments in healthcare [27][30] - **Pricing**: Prefilled syringes priced between $1.50 to $6, compared to standard syringes priced at $0.10 to $0.50 [29][53] - **Demand for Injectable Filling Capacity**: Major pharmaceutical companies are investing heavily in filling technology, indicating strong market demand [35] Financial Health - **Debt-Free Status**: The company has no debt and approximately $12 million in cash [10][45] - **Market Capitalization**: Estimated around $6 million [45] Future Outlook - **Production Capacity**: Expected to ramp up to 120 million to 130 million units per year starting in year two of the sales agreement [25][50] - **Expansion Plans**: Potential to grow beyond the initial sales agreement with additional purchase orders anticipated [41][52] Additional Important Information - **Regulatory Approvals**: Products are FDA approved, CE marked, and WHO approved, highlighting the regulatory compliance necessary in the healthcare sector [6] - **Team Experience**: Leadership team has extensive experience in drug manufacturing and packaging, enhancing investor confidence [36][37] - **Market Trends**: Increasing demand for GLP-1 drugs and the transition to prefilled syringes and auto injectors are expected to drive future growth [52][53] This summary encapsulates the key points discussed during the Sharps Technology conference call, providing insights into the company's operations, market position, and future growth potential.

Summary of Sharps Technology Conference Call Company Overview - **Company**: Sharps Technology (STSS) - **Industry**: Specialized drug delivery systems, focusing on safety syringes and prefilled syringes [4][5] Key Points and Arguments - **IPO and Funding**: Sharps Technology went public in April 2022, raising approximately $16 million to acquire a facility in Hungary and commercialize its products [5] - **Acquisition of Safeguard Medical Facility**: The acquisition of a syringe operation in Hungary provided Sharps with its own intellectual property and advanced technology [5][6] - **Sales Agreements**: - A significant $50 million revenue agreement for specialized Sologuard products with a US contract filler in Texas was secured, marking a transformational opportunity for the business [7][20] - Ongoing negotiations for prefilled syringes in South Carolina, although facing some challenges [6][7] - **Manufacturing Plans**: - Plans to scale up manufacturing capabilities in Hungary and South Carolina, with new equipment expected to be operational by Q4 [8][10][22] - The facility in Hungary is fully operational and capable of scaling up to 100,000 square feet, supporting both smart safety syringe technology and prefilled syringe technology [9][10][15] - **Product Development**: - Focus on SecurGuard and Sologuard products, which include advanced safety features and low waste capabilities [11][19] - Prefilled syringes made from copolymer materials are positioned as a high-growth area, offering advantages over traditional glass syringes [12][13][27] - **Market Trends**: - The syringe market is experiencing significant growth, with a shift from glass vials to prefilled syringes, driven by pharmaceutical companies' investments [24][25] - The prefilled syringe market is expected to overtake disposable syringes in the long term [25] - **Competitive Advantage**: - Sharps Technology's products feature low waste technology, which minimizes drug loss during administration, and reuse prevention capabilities, addressing safety concerns [50][51] - The company aims to carve out a niche in the specialty syringe market by leveraging relationships with healthcare providers [42][43] Additional Important Information - **Financial Position**: The company reported a strong cash position of over $11 million with no debt, and a market cap of $6 million [37] - **Future Plans**: Sharps is committed to expanding its prefilled syringe capabilities, with potential announcements expected by the end of the year [36] - **Industry Context**: Competitors like Eli Lilly and Schott are making significant investments in drug filling capabilities, indicating a growing demand for specialized packaging solutions [29][30] This summary encapsulates the key insights from the Sharps Technology conference call, highlighting the company's strategic direction, market opportunities, and competitive positioning within the specialized drug delivery industry.

Presentation Access: This will be a live, interactive online event where investors are invited to ask the company questions in real- time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. Sharps recently announced that the Company has commenced shipments under three customer orders tied to previously announced purchase agreements. These shipments represent the Company's first commercial deliveries and its transiti ...

Company Overview - Sharps Technology, Inc. is an innovative medical device and pharmaceutical packaging company that offers patented smart safety syringe products to the healthcare industry [6] - The company focuses on ultra-low waste capabilities and incorporates both passive and active safety features in its syringe technologies [6] - Sharps has a manufacturing facility in Hungary that has undergone significant upgrades to support high-volume production [2][6] Recent Developments - Sharps has commenced shipments under three customer orders tied to previously announced purchase agreements, marking its first commercial deliveries and transition to revenue-generating operations [2] - The company will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET, providing an opportunity for investors to gain insights into its operations and future prospects [1][8] Investor Engagement - The Investor Summit is tailored for investors focused on small- and micro-cap stocks, offering insights from management teams of emerging companies [3][4] - Registration for the Investor Summit is available for free, allowing investors to participate and learn more about Sharps and other companies [5]

Sharps Technology, Inc. STSS stock is trading higher on Wednesday.As per data from Benzinga Pro, session volume stands at 31.74 million versus an average volume of 674.72k.What Happened: The medical device and pharmaceutical packaging company initiated shipments for previously announced purchase orders across three customer orders.These shipments mark the company’s first deliveries of its SecureGard and SoloGard product lines and its transition to generating commercial revenue.“These initial shipments mark ...

Sharps has initiated shipment of its first commercial order of Sologard under a previously announced $50 million supply agreement with a U.S.-based leader in IV flushing solutions. The delivery includes customized 10mL SoloGard smart safety syringes manufactured at the Company's upgraded facility in Hungary. SoloGard is a specialized, FDA- and WHO-approved smart safety syringe featuring ultra-low waste design, standard luer lock compatibility, and re-use prevention technology. This inaugural $400,000 purcha ...

Summary of Sharps Technology (STSS) Conference Call - May 22, 2025 Company Overview - **Company**: Sharps Technology (STSS) - **Industry**: Medical Devices, specifically focusing on syringe technology Key Points and Arguments 1. **Sales Agreement**: The company executed a $50,000,000 sales agreement with a large US filler for 10 ml syringes, signed in July 2024, which will utilize most of the capacity of their European facility [1][2] 2. **Expansion Potential**: The agreement has the potential to expand production by an additional 250 million units, supported by a financial raise with Aegis to enhance equipment and technology [2] 3. **Facility Details**: The European facility is debt-free and specializes in smart safety syringe technology, with plans for scalability and expansion to meet contract demands [2][3] 4. **US Manufacturing Facility**: The company is actively seeking a US manufacturing facility, particularly in South Carolina, to produce prefillable syringes using advanced copolymer technology, which is seen as a significant growth area in drug delivery [3][4] 5. **Product Overview**: Current products include SecurGuard and Solarguard syringes, which feature low waste technology and passive safety mechanisms [4][5] 6. **Market Growth**: The prefilled syringe market is rapidly growing, with significant investments from healthcare companies, indicating a strong opportunity for organic growth and partnerships [8][9] 7. **Regulatory Challenges**: The medical device industry has a lengthy lifecycle from concept to commercialization, requiring extensive regulatory approvals [14][15] 8. **Revenue Generation**: The company anticipates early revenue generation in Q2 2025 from initial shipments to the US customer, with a commitment for ongoing orders as production scales [7][28] 9. **Debt Status**: The company is currently debt-free after using part of a $20,000,000 financing to pay down previous loans [25] 10. **Future Projections**: Plans to be cash flow positive by next year, with strategic projects aimed at bringing prefillable syringes to market [35] Additional Important Information 1. **Reverse Stock Split**: A reverse stock split was executed to comply with Nasdaq requirements, which is expected to enhance long-term value for investors [21][31] 2. **Warrant Structure**: Most warrants have been eliminated, improving the company's financial position [33] 3. **Market Demand**: There is increasing demand for prefilled syringes, with copolymer technology offering advantages over traditional glass syringes, such as reduced breakage and improved manufacturing processes [40][42] 4. **Production Capabilities**: The Hungarian facility is positioned to support both current and future production demands, with potential for expansion and flexibility in product offerings [50][52] This summary encapsulates the key insights from the conference call, highlighting Sharps Technology's strategic initiatives, market opportunities, and operational capabilities within the medical device industry.

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, announces that it has received a notice from Nasdaq confirming that the Company has regained compliance with The Nasdaq's Capital Market's minimum bid price requirement of $1.00 per share and the minimum stockholders’ equity requirement of $2.5 mi ...